{"organizations": [], "uuid": "09da81879e56fb6be26b16c935eec5a899dfa41e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/02/pr-newswire-bio-techne-declares-dividend.html", "country": "US", "domain_rank": 767, "title": "Bio-Techne Declares Dividend", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T15:00:00.000+03:00", "replies_count": 0, "uuid": "09da81879e56fb6be26b16c935eec5a899dfa41e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/02/pr-newswire-bio-techne-declares-dividend.html", "ord_in_thread": 0, "title": "Bio-Techne Declares Dividend", "locations": [], "entities": {"persons": [{"name": "bo", "sentiment": "negative"}, {"name": "david clair", "sentiment": "none"}], "locations": [{"name": "minneapolis", "sentiment": "none"}], "organizations": [{"name": "bio-techne corporation", "sentiment": "negative"}, {"name": "bio-techne", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MINNEAPOLIS, May 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2018. The quarterly dividend will be payable May 25, 2018 to all common shareholders of record on May 14, 2018. Future cash dividends will be considered by the Board of Directors on a quarterly basis.\nBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com .\nContact:\nDavid Clair, Investor Relations\nir@bio-techne.com\n646-277-1266\nView original content with multimedia: http://www.prnewswire.com/news-releases/bio-techne-declares-dividend-300640710.html\nSOURCE Bio-Techne Corporation", "external_links": ["http://www.prnewswire.com/news-releases/bio-techne-declares-dividend-300640710.html", "http://www.bio-techne.com/"], "published": "2018-05-02T15:00:00.000+03:00", "crawled": "2018-05-02T15:49:39.028+03:00", "highlightTitle": ""}